As an investor, it can be very challenging to decide whether the Gaudium IVF IPO is a good or bad investment. Not anymore. On this blog, we will provide you with all the necessary details related to the Gaudium IVF IPO to help you decide whether to Apply or Not. Read on to know the IPO risks, strengths, valuation, financial details, and expert opinion to make your investment decision better.
Strengths:
- The firm has consistently maintained an IVF success rate of over 57%, which is considered quite strong.
- Its ROE in FY25 is over 41%, indicating healthy financials.
- Experienced fertility specialists and an expert team with over 20 years of experience in infertility treatment.
- Gaudium IVF has won multiple awards over the years. The firm was ranked Asia’s Greatest Brands 2016 in Singapore, Symbol of Brand Excellence Award (2018) in London, and India Best Practices Award – IVF Chain Company in 2019.
Weaknesses:
- As of September 2025, the firm has contingent liabilities of ₹4,499.34 lakhs. If they have to pay the liabilities tomorrow, then it can adversely affect the business and its financial situation.
- The company offers various healthcare treatments like IVF, IUI, ICSI, egg freezing, and many other procedures. If they fail to provide good quality treatment or fail to maintain patient care, it can badly impact the business, reputation, and financial performance.
- As of September 2025, Gaudium IVF’s attrition rate is 31%. Since the firm mainly depends on doctors, nurses, and healthcare professionals, any inability to attract or retain the staff can badly affect the business.
- In FY25, the firm has experienced a negative cash flow of ₹15.17 Crores from investing activities.
Gaudium IVF IPO Review
| Reviewer | Recommendation |
| IPO Watch | May Apply |
| Canara Bank | |
| Swastika Investmart | Apply |
| Emkay Global | |
| Hem Securities | |
| IDBI Capital | |
| Marwadi Shares | |
| Nirmal Bang | |
| SBICAP Securities | |
| Sharekhan | |
| SMC Global | |
| Sushil Finance | |
| Swastika Investmart | |
| Ventura Securities | |
| Geojit | |
| Reliance Securities | |
| Capital Market | |
| BP Wealth | |
| ICICIdirect | |
| Choice Broking |
Peer Comparison with the Company
| Name of the Company | Face Value(₹) | Basic EPS (₹) | RONW (%) | P/E Ratio | NAV(₹) |
| Gaudium IVF and Women’s Health Limited | 5 | 3.12 | 41.71% | 25.36 | 7.54 |
| Peer Groups | |||||
| Progyny Inc. | $0.0001 | 50.52 | 12.90% | 41.56 | 394.20 |
| Inspire IVF Public Company Limited | THB 0.05 | 0.17 | 3.97% | 11.43 | 4.34 |
Industry P/E ratio
In the healthcare/Fertility Clinics sector, the industry P/E ratio ranges from a low of 11.43 to a high of 41.56, with an average of 26.49.
Promoters & Track Records, if any
- Dr. Manika Khanna is the Promoter and the Managing Director of the Company. She holds 6,09,73,900 Equity shares, representing 99.32% of the paid-up equity capital in the company.
- Dr. Peeyush Khanna is the Promoter and the Whole Time Director of the Company. He holds 2,21,092 Equity shares, representing 0.36% of the paid-up equity capital.
- Vishad Khanna is the Promoter and the Non-Executive Director of the Company. He holds 1,86,000 Equity shares, representing 0.30% of the paid-up equity capital.
Expansion
- The proceeds of ₹50 crore raised from the fresh issue will be used towards the establishment of the New IVF Centers of the Company.
- The fund of ₹20 crore will be used for the repayment/prepayment of certain borrowings taken by the company.
- Lastly, the remaining funds will be used for the expansion of its assets and general corporate purposes.
Gaudium IVF IPO – Should You Apply or Not?
Gaudium IVF and women’s health was established for mothers who want to experience motherhood. Their mission was to help couples who face challenges to grow a family due to infertility or medical issues. Founded in 2015, the firm specializes in IVF treatments to deliver motherhood dreams. The firm provides various fertility and reproductive health services such as IVF, ICSI, IUI, ovulation induction, and all treatments of infertility challenges for both male and female. In FY25, the firm generated ₹70.96 crore in revenue from operations, up from ₹48.15 crore in FY24, indicating a 47.37% increase. The PAT also increased to ₹19.13 crores in FY25, showcasing strong financial health. Upon calculation, the P/E ratio of Gaudium IPO is 25.36x, which, when compared to industry peers, looks fair and decent. As of February 17, the Gaudium IVF IPO GMP is ₹0.
Overall, Guadium IVF IPO features a strong brand presence in the fertility segment, sound financials, a well-managed hub-and-spoke model, and a high success rate supports future growth and long-term growth. However, high employee attrition, significant contingent liabilities, negative cash flow, and medical risks are key risks investors should keep in mind.
If the overall market sentiment and GMP stay in support, then investors can subscribe for the IPO for short-term gains. While cautious investors must analyze the risks associated with companies, such as operational and medical risks and financial stability, before subscribing.
Please note:
Investors are advised to make their own decisions and apply entirely at their own risk. This article is written using information from the company’s RHP (Red Herring Prospectus) data and online sources. If you have any queries, kindly contact the IPO Watch Team.
